Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden.

Schramm SJ, Li SS, Jayaswal V, Fung DC, Campain AE, Pang CN, Scolyer RA, Yang YH, Mann GJ, Wilkins MR.

Pigment Cell Melanoma Res. 2013 Sep;26(5):708-22. doi: 10.1111/pcmr.12126. Epub 2013 Jul 5.

PMID:
23738911
2.

MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.

Tembe V, Schramm SJ, Stark MS, Patrick E, Jayaswal V, Tang YH, Barbour A, Hayward NK, Thompson JF, Scolyer RA, Yang YH, Mann GJ.

Pigment Cell Melanoma Res. 2015 May;28(3):254-66. doi: 10.1111/pcmr.12343. Epub 2015 Jan 5.

PMID:
25490969
3.

MicroRNAs in malignant melanoma.

Völler D, Ott C, Bosserhoff A.

Clin Biochem. 2013 Jul;46(10-11):909-17. doi: 10.1016/j.clinbiochem.2013.01.008. Epub 2013 Jan 27. Review.

PMID:
23360785
4.

VAN: an R package for identifying biologically perturbed networks via differential variability analysis.

Jayaswal V, Schramm SJ, Mann GJ, Wilkins MR, Yang YH.

BMC Res Notes. 2013 Oct 25;6:430. doi: 10.1186/1756-0500-6-430.

5.

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.

Bucheit AD, Syklawer E, Jakob JA, Bassett RL Jr, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA.

Cancer. 2013 Nov 1;119(21):3821-9. doi: 10.1002/cncr.28306. Epub 2013 Aug 6.

6.

The role of microRNAs in melanoma.

Luo C, Weber CE, Osen W, Bosserhoff AK, Eichmüller SB.

Eur J Cell Biol. 2014 Jan-Feb;93(1-2):11-22. doi: 10.1016/j.ejcb.2014.02.001. Epub 2014 Feb 11. Review.

PMID:
24602414
7.

Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.

Schlaak M, Bajah A, Podewski T, Kreuzberg N, von Bartenwerffer W, Wardelmann E, Merkelbach-Bruse S, Büttner R, Mauch C, Kurschat P.

Br J Dermatol. 2013 Apr;168(4):708-16. doi: 10.1111/bjd.12140.

PMID:
23528057
8.

MicroRNA regulation of melanoma progression.

Bonazzi VF, Stark MS, Hayward NK.

Melanoma Res. 2012 Apr;22(2):101-13. doi: 10.1097/CMR.0b013e32834f6fbb. Review.

PMID:
22209751
9.

Association of galectin-3 expression with melanoma progression and prognosis.

Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, Bartlett JM, Smyth JF, Melton DW.

Eur J Cancer. 2012 Apr;48(6):865-74. doi: 10.1016/j.ejca.2011.09.003. Epub 2011 Nov 7.

PMID:
22071132
10.

Cell cycle gene networks are associated with melanoma prognosis.

Wang L, Hurley DG, Watkins W, Araki H, Tamada Y, Muthukaruppan A, Ranjard L, Derkac E, Imoto S, Miyano S, Crampin EJ, Print CG.

PLoS One. 2012;7(4):e34247. doi: 10.1371/journal.pone.0034247. Epub 2012 Apr 20.

11.

Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.

Jayawardana K, Schramm SJ, Tembe V, Mueller S, Thompson JF, Scolyer RA, Mann GJ, Yang J.

J Invest Dermatol. 2016 Jan;136(1):245-54. doi: 10.1038/JID.2015.355. Review.

12.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer.

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

PMID:
16595783
13.

Human melanomas of fibroblast and epithelial morphology differ widely in their ability to synthesize retinyl esters.

Simmons DP, Andreola F, De Luca LM.

Carcinogenesis. 2002 Nov;23(11):1821-30.

PMID:
12419830
14.

Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.

Jönsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringnér M, Lillehaug JR, Borg A, Lønning PE.

Clin Cancer Res. 2010 Jul 1;16(13):3356-67. doi: 10.1158/1078-0432.CCR-09-2509. Epub 2010 May 11.

15.

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.

Lázár V, Ecsedi S, Szöllosi AG, Tóth R, Vízkeleti L, Rákosy Z, Bégány A, Adány R, Balázs M.

Mod Pathol. 2009 Oct;22(10):1367-78. doi: 10.1038/modpathol.2009.109. Epub 2009 Jul 24.

16.

Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.

Lázár V, Ecsedi S, Vízkeleti L, Rákosy Z, Boross G, Szappanos B, Bégány A, Emri G, Adány R, Balázs M.

Melanoma Res. 2012 Jun;22(3):202-14. doi: 10.1097/CMR.0b013e328352dbc8.

PMID:
22456166
17.

Melanoma inhibitory activity promotes melanoma development through activation of YBX1.

Schmid R, Meyer K, Spang R, Schittek B, Bosserhoff AK.

Pigment Cell Melanoma Res. 2013 Sep;26(5):685-96. doi: 10.1111/pcmr.12119. Epub 2013 Jun 14.

PMID:
23672612
18.

Gene expression profiling of primary cutaneous melanoma.

Winnepenninckx V, Van den Oord JJ.

Verh K Acad Geneeskd Belg. 2007;69(1):23-45. Review.

PMID:
17427873
19.

Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.

Safaee Ardekani G, Jafarnejad SM, Khosravi S, Martinka M, Ho V, Li G.

Br J Dermatol. 2013 Aug;169(2):320-8. doi: 10.1111/bjd.12351.

PMID:
23550516
20.

Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information.

Jayawardana K, Schramm SJ, Haydu L, Thompson JF, Scolyer RA, Mann GJ, Müller S, Yang JY.

Int J Cancer. 2015 Feb 15;136(4):863-74. doi: 10.1002/ijc.29047. Epub 2014 Jul 24.

Supplemental Content

Support Center